PURPOSE: The purpose of this study is to assess treatment responses induced by the two tyrosine kinase inhibitors, Imatinib and Sunitinib, in a gastrointestinal stromal tumor (GIST) xenograft using a clinical positron emission tomography/computed tomography (PET/CT) scanner. METHODS: Nude mice bearing human GIST xenografts with mutations in exons 11 and 17 were randomly allocated to treatment with Imatinib, Sunitinib, or placebo daily for seven consecutive days. 2-deoxy-2-[(18)F]fluoro-D: -glucose PET ((18)F-FDG-PET/CT) was performed in a clinical PET/CT scanner at baseline (day 0) and 1 and 7 days after onset of treatment. Treatment response was assessed by measuring tumor volumes and by calculation of tumor-to-liver (18)F-FDG uptake ratios. RESULTS: Minor reductions in tumor volume were observed in both treatment groups. For the two treatment groups, significantly decreased tumor-to-liver uptake ratios were observed both at day 1 (Imatinib, -41%, p = .002; Sunitinib, -55%, p < .001) and at day 8 (Imatinib, -35%, p < .001; Sunitinib, -50%, p < .001), when compared to individual baseline values. For the control tumors, neither tumor volumes nor tumor-to-liver uptake ratios were altered during the 8 days the experiment lasted. CONCLUSIONS: Significant anti-tumor effects were demonstrated following treatment with both Imatinib and Sunitinib. Decreased tumor-to-liver uptake ratios were more pronounced than tumor volume reductions. Effects of novel targeted therapies can be evaluated in the GIST xenograft model using a clinical PET/CT scanner.
PURPOSE: The purpose of this study is to assess treatment responses induced by the two tyrosine kinase inhibitors, Imatinib and Sunitinib, in a gastrointestinal stromal tumor (GIST) xenograft using a clinical positron emission tomography/computed tomography (PET/CT) scanner. METHODS:Nude mice bearing human GIST xenografts with mutations in exons 11 and 17 were randomly allocated to treatment with Imatinib, Sunitinib, or placebo daily for seven consecutive days. 2-deoxy-2-[(18)F]fluoro-D: -glucose PET ((18)F-FDG-PET/CT) was performed in a clinical PET/CT scanner at baseline (day 0) and 1 and 7 days after onset of treatment. Treatment response was assessed by measuring tumor volumes and by calculation of tumor-to-liver (18)F-FDG uptake ratios. RESULTS: Minor reductions in tumor volume were observed in both treatment groups. For the two treatment groups, significantly decreased tumor-to-liver uptake ratios were observed both at day 1 (Imatinib, -41%, p = .002; Sunitinib, -55%, p < .001) and at day 8 (Imatinib, -35%, p < .001; Sunitinib, -50%, p < .001), when compared to individual baseline values. For the control tumors, neither tumor volumes nor tumor-to-liver uptake ratios were altered during the 8 days the experiment lasted. CONCLUSIONS: Significant anti-tumor effects were demonstrated following treatment with both Imatinib and Sunitinib. Decreased tumor-to-liver uptake ratios were more pronounced than tumor volume reductions. Effects of novel targeted therapies can be evaluated in the GIST xenograft model using a clinical PET/CT scanner.
Authors: H Joensuu; P J Roberts; M Sarlomo-Rikala; L C Andersson; P Tervahartiala; D Tuveson; S Silberman; R Capdeville; S Dimitrijevic; B Druker; G D Demetri Journal: N Engl J Med Date: 2001-04-05 Impact factor: 91.245
Authors: S Hirota; K Isozaki; Y Moriyama; K Hashimoto; T Nishida; S Ishiguro; K Kawano; M Hanada; A Kurata; M Takeda; G Muhammad Tunio; Y Matsuzawa; Y Kanakura; Y Shinomura; Y Kitamura Journal: Science Date: 1998-01-23 Impact factor: 47.728
Authors: Dirk B Mendel; A Douglas Laird; Xiaohua Xin; Sharianne G Louie; James G Christensen; Guangmin Li; Randall E Schreck; Tinya J Abrams; Theresa J Ngai; Leslie B Lee; Lesley J Murray; Jeremy Carver; Emily Chan; Katherine G Moss; Joshua O Haznedar; Juthamas Sukbuntherng; Robert A Blake; Li Sun; Cho Tang; Todd Miller; Sheri Shirazian; Gerald McMahon; Julie M Cherrington Journal: Clin Cancer Res Date: 2003-01 Impact factor: 12.531
Authors: Anne-Marie O'Farrell; Tinya J Abrams; Helene A Yuen; Theresa J Ngai; Sharianne G Louie; Kevin W H Yee; Lily M Wong; Weiru Hong; Leslie B Lee; Ajia Town; Beverly D Smolich; William C Manning; Lesley J Murray; Michael C Heinrich; Julie M Cherrington Journal: Blood Date: 2003-01-16 Impact factor: 22.113
Authors: Harvey Hensley; Karthik Devarajan; James R Johnson; David Piwnica-Worms; Andrew K Godwin; Margaret von Mehren; Lori Rink Journal: Cancer Biol Ther Date: 2014-04-22 Impact factor: 4.742
Authors: Neale S Mason; Brian J Lopresti; James Ruszkiewicz; Xinxin Dong; Sonali Joyce; George Leef; Malabika Sen; Abdus S Wahed; Chester A Mathis; Jennifer R Grandis; Sufi M Thomas Journal: Am J Nucl Med Mol Imaging Date: 2013-01-05